Pilatus Biosciences Receives Hong Kong Clinical Trial Authorization for PLT012 and Expands Asia-Pacific Presence with New Regional Subsidiary
Pilatus Biosciences, Inc., a clinical-stage biopharmaceutical company focused on developing innovative metabolic checkpoint immunotherapies for liver and gastrointestinal cancers, has announced two significant milestones that strengthen its global development strategy. The company has received authorization from the Hong Kong Department of Health to initiate a clinical trial of its lead investigational therapy, PLT012, in patients with advanced solid tumors. At the same time, Pilatus has officially established a wholly owned subsidiary in Hong Kong, reinforcing its commitment to expanding clinical development and strategic collaborations across the Asia-Pacific region.
The regulatory approval enables Pilatus Biosciences to begin evaluating PLT012 in a Phase I clinical study at one of Hong Kong’s leading oncology research institutions. The company believes this milestone marks an important step toward advancing a first-in-class therapeutic candidate designed to target metabolic pathways involved in cancer progression and immune regulation.
By combining regulatory progress with a stronger regional presence, Pilatus aims to accelerate the global development of PLT012 while building partnerships with academic institutions, biotechnology organizations, healthcare providers, and investors throughout Asia.
Regulatory Approval Advances Global Clinical Development
The Hong Kong Department of Health has granted Pilatus Biosciences a Certificate for Clinical Trial/Medicinal Test (CTA) for PLT012, allowing the company to initiate a Phase I clinical study in patients with advanced solid tumors.
Clinical trial authorization represents a critical regulatory milestone in the development of any investigational therapy. Before human studies can begin, regulators carefully review preclinical research, manufacturing data, safety information, and proposed clinical protocols to determine whether a therapy is suitable for evaluation in patients.
With the CTA now in place, Pilatus is authorized to begin clinical evaluation of PLT012 in Hong Kong under carefully monitored conditions.
The company views the approval as an important component of its broader international development strategy aimed at evaluating PLT012 across multiple geographic regions.
Phase I Study to Be Conducted at The Chinese University of Hong Kong
The upcoming clinical study will be conducted at the Phase I Clinical Trial Centre within the Department of Clinical Oncology at The Chinese University of Hong Kong (CUHK).
The institution is recognized for its expertise in early-stage oncology research and clinical trials, making it an important partner for evaluating innovative cancer therapies.
The study will focus on patients with advanced solid tumors, including:
- Liver cancer
- Gastrointestinal cancers
- Other advanced solid malignancies
As a Phase I study, the primary objectives will include evaluating the safety, tolerability, and clinical profile of PLT012 while collecting early information regarding its biological activity.
The results generated from this study are expected to help guide subsequent stages of clinical development.
Addressing Unmet Needs in Advanced Solid Tumors
Advanced solid tumors remain among the most challenging diseases to treat, particularly when patients no longer respond to available therapies.
Liver cancer and gastrointestinal malignancies continue to account for a substantial proportion of cancer-related deaths worldwide.
Although targeted therapies, chemotherapy, immunotherapy, and combination treatment strategies have improved outcomes for many patients, long-term survival remains limited for advanced disease.
Researchers continue investigating novel therapeutic approaches capable of overcoming treatment resistance and improving anti-tumor immune responses.
Pilatus Biosciences believes PLT012 may offer a differentiated mechanism capable of addressing important biological pathways involved in cancer progression.
By targeting metabolic dysfunction and inflammation, the company hopes to expand therapeutic options for patients with significant unmet medical needs.
PLT012: A First-in-Class CD36-Targeted Therapy
PLT012 is the lead investigational therapy within Pilatus Biosciences’ development pipeline.
The therapy has been designed as a first-in-class therapeutic targeting CD36, a receptor involved in multiple biological processes associated with metabolism, inflammation, and immune regulation.
CD36 has attracted increasing scientific interest because of its role in:
- Metabolic dysfunction
- Lipid metabolism
- Chronic inflammation
- Tumor progression
- Immune suppression within the tumor microenvironment
Emerging research suggests that modulation of CD36 may influence both cancer biology and immune responses, making it a promising target for next-generation immunotherapies.
Rather than directly targeting tumor cells alone, PLT012 seeks to influence metabolic pathways that contribute to cancer development and progression.
This differentiated mechanism has the potential to complement existing oncology treatment approaches while addressing biological processes that have traditionally been difficult to target.
Advancing Metabolic Checkpoint Immunotherapy
Pilatus Biosciences specializes in developing metabolic checkpoint immunotherapies, an emerging area of cancer research focused on regulating metabolic pathways that influence immune function.
Traditional immunotherapies often target immune checkpoint proteins such as PD-1, PD-L1, or CTLA-4.
Metabolic checkpoint therapies instead aim to modify the metabolic environment surrounding tumors, potentially improving immune cell function while disrupting pathways that support cancer growth.
This rapidly evolving field seeks to overcome limitations associated with current immunotherapies by addressing additional mechanisms of immune suppression.
PLT012 represents Pilatus’ lead effort to translate these scientific concepts into clinical therapies for patients with difficult-to-treat cancers.
Hong Kong Expansion Supports Regional Growth
Alongside the clinical trial authorization, Pilatus Biosciences announced the establishment of its new Hong Kong subsidiary.
The new regional operation strengthens the company’s presence within one of Asia’s fastest-growing biotechnology and life sciences ecosystems.
Hong Kong has increasingly become an important destination for biotechnology companies due to its:
- International regulatory environment
- Advanced healthcare infrastructure
- Strong academic institutions
- Growing biotechnology investment community
- Strategic geographic location
The company expects its regional office to serve as a hub supporting clinical operations, scientific collaborations, and business development throughout the Asia-Pacific region.
Collaboration with Invest Hong Kong
Pilatus worked closely with Invest Hong Kong (InvestHK) during the establishment of its regional operations.
InvestHK supports international companies seeking to establish business activities within Hong Kong by providing guidance, networking opportunities, and assistance with market entry.
Through this collaboration, Pilatus intends to leverage Hong Kong’s expanding biotechnology ecosystem to advance multiple strategic initiatives.
These include:
- Clinical development
- Academic research collaborations
- Strategic industry partnerships
- Regional investment opportunities
- Expansion of scientific networks
The company believes these relationships will help strengthen its long-term presence within Asia while supporting global development of PLT012.
Investigator Highlights Clinical Significance
Dr. Stephen Chan, principal investigator for the study and Clinical Professor within the Department of Clinical Oncology at The Chinese University of Hong Kong, welcomed the regulatory approval.
He noted that receipt of the Clinical Trial Authorization enables the clinical evaluation of PLT012 to begin in Hong Kong.
According to Dr. Chan, the research team looks forward to working closely with Pilatus Biosciences to evaluate the investigational therapy’s safety profile and clinical potential in patients with advanced solid tumors.
His comments underscore the importance of collaboration between biotechnology companies and academic medical centers in advancing early-stage oncology research.
Company Leadership Outlines Strategic Vision
Raven Lin, Chief Executive Officer and Co-founder of Pilatus Biosciences, described the Hong Kong expansion as an important milestone within the company’s global development strategy.
He emphasized that Hong Kong offers a world-class clinical research environment supported by a strong regulatory framework and an increasingly vibrant biotechnology sector.
Lin also expressed appreciation for the assistance provided by InvestHK during establishment of the company’s regional operations.
According to him, Pilatus intends to become an active participant within Hong Kong’s innovation ecosystem while continuing to advance PLT012 through clinical development.
The company’s long-term strategy includes strengthening regional collaborations while expanding opportunities for future investment and scientific partnerships.
Strengthening Presence Across Asia
The establishment of Pilatus’ Hong Kong subsidiary provides several strategic advantages beyond supporting the ongoing clinical trial.
The regional office is expected to facilitate:
- Closer collaboration with Asian academic institutions
- Expanded clinical trial opportunities
- Increased engagement with regional biotechnology partners
- Access to new investment communities
- Enhanced operational support for future development programs
As oncology drug development becomes increasingly global, establishing regional infrastructure enables biotechnology companies to accelerate recruitment, improve collaboration, and broaden access to diverse patient populations.
Pilatus views Hong Kong as an ideal location from which to coordinate these activities.
The receipt of Clinical Trial Authorization from the Hong Kong Department of Health and the establishment of a new regional subsidiary represent two important milestones in Pilatus Biosciences’ continued growth as a clinical-stage oncology company. Together, these achievements strengthen the company’s ability to advance PLT012, its first-in-class CD36-targeted metabolic checkpoint immunotherapy, while expanding its footprint within one of Asia’s leading biotechnology and clinical research hubs.
As the Phase I clinical study begins at The Chinese University of Hong Kong, Pilatus will generate important safety and early clinical data that could help shape the future development of PLT012 for patients with advanced solid tumors, including liver and gastrointestinal cancers. At the same time, the company’s expanded presence in Hong Kong positions it to build stronger regional collaborations, engage with strategic partners and investors, and accelerate the global development of innovative therapies aimed at addressing significant unmet needs in oncology.
About PLT012
PLT012 is a humanized monoclonal antibody designed to selectively block CD36-mediated lipid uptake, a key mechanism driving immunosuppression and immune exclusion within the tumor microenvironment. By targeting lipid metabolism, PLT012 exerts a unique mechanism of action: it depletes immunosuppressive cell populations, including Tregs and pro-tumor macrophages, while simultaneously enhancing antitumor activities of intratumoral NK cell and cytotoxic CD8+ T cell that are otherwise susceptible to lipid-induced exhaustion.
In preclinical studies, PLT012 has demonstrated potent monotherapy efficacy in models of liver malignancies, with a favorable safety profile across species. Leveraging its distinct mechanism of action, PLT012 further acts as a potent sensitizer in combination with anti–PD-L1 therapies, effectively overcoming drug resistance in immune “cold” tumors and liver metastases.
About Pilatus Biosciences
Pilatus Biosciences is a clinical-stage biopharmaceutical company developing metabolic checkpoint immunotherapies to address unmet medical needs in cancer and immune-related diseases. Founded in 2022 from the Ludwig Institute for Cancer Research, and supported by the Cancer Research Institute, Pilatus operates internationally with R&D teams in Switzerland and Taiwan. The company’s lead program, PLT012, targets CD36 to reprogram the tumor microenvironment and restore anti-tumor immunity in solid tumors.